Recent Analysts’ Ratings Changes for Fulcrum Therapeutics (FULC)

Fulcrum Therapeutics (NASDAQ: FULC) has recently received a number of price target changes and ratings updates:

• 6/3/2026 – Fulcrum Therapeutics was downgraded by JPMorgan Chase & Co. from “overweight” to “underweight”.
• 6/2/2026 – Fulcrum Therapeutics was downgraded by Citigroup Inc. from “underperform” to “underweight”.
• 6/2/2026 – Fulcrum Therapeutics was given a new $4.00 price target by Jefferies Financial Group Inc..
• 6/2/2026 – Fulcrum Therapeutics was downgraded by Truist Financial Corporation from “buy” to “hold”. They now have a $4.00 price target on the stock.
• 6/2/2026 – Fulcrum Therapeutics was downgraded by Piper Sandler from “overweight” to “neutral”. They now have a $3.00 price target on the stock.
• 6/2/2026 – Fulcrum Therapeutics was downgraded by Cantor Fitzgerald from “strong-buy” to “hold”.
• 6/2/2026 – Fulcrum Therapeutics was downgraded by Leerink Partners from “outperform” to “market perform”. They now have a $4.00 price target on the stock.
• 6/2/2026 – Fulcrum Therapeutics was downgraded by Stifel Nicolaus from “buy” to “hold”. They now have a $3.00 price target on the stock.
• 6/2/2026 – Fulcrum Therapeutics was downgraded by HC Wainwright from “buy” to “neutral”. They now have a $3.00 price target on the stock.
• 5/2/2026 – Fulcrum Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 4/21/2026 – Fulcrum Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.